| Lian Chen,Ling Wu,Zhang Lu,Qin Huang,Liu Huang. Treatment-related adverse events of combined anti-angiogenic and immune checkpoint inhibitors: systematic review and meta-analysis. Oncol Transl Med, 2022, 8: 301-310. |
| Treatment-related adverse events of combined anti-angiogenic and immune checkpoint inhibitors: systematic review and meta-analysis |
| Received:October 28, 2022 Revised:October 28, 2022 |
| View Full Text View/Add Comment Download reader |
| KeyWord:combination therapy, immune checkpoint inhibitor, angiogenesis inhibitor, treatment-related adverse events, systematic review, meta-analysis |
| Author Name | Affiliation | E-mail | | Lian Chen | Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology | 6212809071@stu.jiangnan.edu.cn | | Ling Wu | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China | | | Zhang Lu | Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China | | | Qin Huang | Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China | | | Liu Huang | Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China | |
|
| Hits: 1633 |
| Download times: 1906 |
| Abstract: |
| Objective Immune checkpoint inhibitor (ICI) plus angiogenesis inhibitor (AI) combination therapy is a
novel treatment model for multiple cancers that normalizes vascular-immune crosstalk to potentiate cancer
immunity. In this review, we summarize the characteristics of adverse effects (AEs) and all fatal cases
reported in clinical studies involing ICI + AI therapy.
Methods Four databases were systematically searched for eligible studies, and 28 relevant studies were
selected for inclusion.
Results Of the patients included, 58.1% developed grade ≥ 3 AEs. The most common fatal AEs were
cardiovascular events, severe infections, and hemorrhage. Compared with AI alone, ICI + AI therapy
resulted in more cases of grade ≥ 3 proteinuria, liver injury, and fatal AEs (2.49% vs. 1.28%, P = 0.0041),
especially respiratory toxicities and severe infections; however, ICI + AI therapy reduced hematological
toxicity.
Conclusion We shared comprehensive and practical safety data to review the adverse events associated
with ICI + AI treatment. |
| Close |
|
|
|